Citizens JMP raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $527 from $485 and keeps an Outperform rating on the shares. Rezdiffra sales of $287M beat consensus estimates, driven by robust demand, with more than 29,500 patients now on the therapy in the U.S., the analyst tells investors in a research note. The firm is looking forward to Madrigal’s presence and MASH leadership at the Liver Meeting, which is kicking off later this week, where Rezdiffra will be featured in numerous presentations covering efficacy, safety, real-world use, quality of life improvements, early biomarkers, and durability of fibrosis regression.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals Reports Strong Q3 2025 Growth
- Madrigal Pharmaceuticals: Strong Market Performance and Strategic Positioning Drive Buy Rating
- Cantor upgrades Madrigal to Overweight on 2026 growth potential
- Madrigal Pharmaceuticals upgraded to Overweight from Neutral at Cantor Fitzgerald
- Madrigal Pharmaceuticals price target raised to $533 from $431 at Clear Street